Next Article in Journal
Health Technology Assessment (HTA) and Economic Evaluation: Efficiency or Fairness First
Previous Article in Journal
Patient-Reported Outcome Claims in European and United States Orphan Drug Approvals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 7
Issue 1
10.1080/20016689.2018.1545514
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Non-Profit Drug Research and Development: The Case Study of Genethon

by
Szymon Jarosławski
and
Mondher Toumi
*
Public Health Department–Research Unit EA 3279, Aix-Marseille University, Marseille, France
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1545514; https://doi.org/10.1080/20016689.2018.1545514
Submission received: 5 July 2018 / Revised: 9 October 2018 / Accepted: 31 October 2018 / Published: 15 November 2018

Abstract

Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms. Like other non-profits, Genethon is willing to adopt an ethical attitude toward their donors by pricing their products affordably. It remains to be seen if the approach to internalize the marketing authorization, manufacturing and distribution activities prove to be efficient and sustainable. Also, the firm faces an ethical dilemma because lower prices of innovative drugs can dry the for-profit R&D in the area and prevent patient access to future innovations.
Keywords: non-profit; research and development; pharmaceutical industry; orphan drugs; pricing; ethics non-profit; research and development; pharmaceutical industry; orphan drugs; pricing; ethics

Share and Cite

MDPI and ACS Style

Jarosławski, S.; Toumi, M. Non-Profit Drug Research and Development: The Case Study of Genethon. J. Mark. Access Health Policy 2019, 7, 1545514. https://doi.org/10.1080/20016689.2018.1545514

AMA Style

Jarosławski S, Toumi M. Non-Profit Drug Research and Development: The Case Study of Genethon. Journal of Market Access & Health Policy. 2019; 7(1):1545514. https://doi.org/10.1080/20016689.2018.1545514

Chicago/Turabian Style

Jarosławski, Szymon, and Mondher Toumi. 2019. "Non-Profit Drug Research and Development: The Case Study of Genethon" Journal of Market Access & Health Policy 7, no. 1: 1545514. https://doi.org/10.1080/20016689.2018.1545514

APA Style

Jarosławski, S., & Toumi, M. (2019). Non-Profit Drug Research and Development: The Case Study of Genethon. Journal of Market Access & Health Policy, 7(1), 1545514. https://doi.org/10.1080/20016689.2018.1545514

Article Metrics

Back to TopTop